देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
IPRATROPIUM BROMIDE
PHARMASCIENCE INC
R03BB01
IPRATROPIUM BROMIDE
250MCG
SOLUTION
IPRATROPIUM BROMIDE 250MCG
INHALATION
20ML
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0115643001; AHFS:
APPROVED
2014-01-20
PRODUCT MONOGRAPH PMS-IPRATROPIUM Ipratropium Bromide Nebulizer Solution 250 mcg/mL (0.025%) in 20 mL Bottles BRONCHODILATOR PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montreal, Quebec H4P 2T4 www.pharmascience.com DATE OF REVISION: May 11, 2017 CONTROL NO.: 204492 _pms-IPRATROPIUM Product Monograph Page 2 of 28_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..................................................... 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................... 4 ADVERSE REACTIONS ...................................................................................................... 7 DRUG INTERACTIONS .................................................................................................... 10 DOSAGE AND ADMINISTRATION ................................................................................ 10 OVERDOSAGE ................................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY............................................................... 11 STORAGE AND STABILITY ............................................................................................ 14 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 15 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 15 PART II: SCIENTIFIC INFORMATION .......................................................................... 16 PHARMACEUTICAL INFORMATION ............................................................................ 16 CLINICAL TRIALS ........................... पूरा दस्तावेज़ पढ़ें